ダウンロード数: 172
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
18_1061.pdf | 634.91 kB | Adobe PDF | 見る/開く |
タイトル: | 骨転移を合併する前立腺癌にかんする臨床的研究 第1編: 臨床的観察とホルモン療法の遠隔成績 |
その他のタイトル: | CLINICAL STUDIES ON CARCINOMA OF THE PROSTATE WITH METASTASIS TO THE BONE PART1.CLINICAL OBSERVATION AND THE END RESULTS OF HORMONE THERAPY |
著者: | 柏木, 崇 ![]() |
著者名の別形: | Kashiwagi, Takashi |
発行日: | Dec-1972 |
出版者: | 京都大学医学部泌尿器科学教室 |
誌名: | 泌尿器科紀要 |
巻: | 18 |
号: | 12 |
開始ページ: | 1061 |
終了ページ: | 1069 |
抄録: | 1. Sixty-three carcinoma of the prostate were experienced for past 7 years and 8 months, April 1964 to Dec. 1971, and followed up. Twenty-five of them (39.7 %) had metastatic bone lesions. Of twenty-nine cases over 71 years of age, 15 (51.7 %) had bone metastasis. 2. The patients without bone lesions mostly visited complaining of dysuria, and 48 % of those with bone lesions complained of lumbago or neuralgic pain of the lower extremities. 3. 37% of those having the bone lesions visited the clinic after spending more than three years from the onset of symptoms, whereas 23.6 % of the non-metastatic group visited after 3 years. 4. The metastatic group showed hydronephrosis or non-visualizing kidney in 10 cases (43.5 %), whereas the non-metastatic group showed such abnormalities only in 8 (22.2%). 5. There was no difference of amount of residual urine between two groups. 6. Metastases were mostly to the lower vertebrae and pelvic bone (72 % in both), and the multiple lesions were seen in 28 %. 7. Histologically, bone metastasis was seen in 18 out of 45 adenocarcinomas (40 %) and in 3 out of 12 undifferentiated carcinomas (30 %). 8. The end results of the anti-androgen therapy expressed by the survival rate were 75.3 % in 3 years and 57.4 % in 5 years in the non-metastatic group which did not differ from the average survival rate of the same generation. 9. The survival rate of the metastatic group was 26.0 % in 2 years and 17.3% in 5 years. Two cases are still alive at 3.25 and 4.25 years. 10. Leading cause of death was cancer (75 %) in the metastatic group and cardiovascular diseases (50 %) in the non-metastatic group. |
URI: | http://hdl.handle.net/2433/121466 |
出現コレクション: | Vol.18 No.12 |
![](/dspace/image/articlelinker.gif)
このリポジトリに保管されているアイテムはすべて著作権により保護されています。